title: Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1.
abstract: We have evaluated the effects of the carbon monoxide-releasing molecule CORM-A1 [Na(2) (BH(3) CO(2) ); ALF421] on the development of relapsing-remitting experimental allergic encephalomyelitis (EAE) in SJL mice, an established model of multiple sclerosis (MS). The data show that the prolonged prophylactic administration of CORM-A1 improves the clinical and histopathological signs of EAE, as shown by a reduced cumulative score, shorter duration and a lower cumulative incidence of the disease as well as milder inflammatory infiltrations of the spinal cords. This study suggests that the use of CORM-A1 might represent a novel therapeutic strategy for the treatment of multiple sclerosis.
authors.affiliation: Department of Biomedical Sciences, School of Medicine, University of Catania, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Fagone
authors.forename: K
authors.initials: K
authors.lastname: Mangano
authors.forename: C
authors.initials: C
authors.lastname: Quattrocchi
authors.forename: R
authors.initials: R
authors.lastname: Motterlini
authors.forename: R
authors.initials: R
authors.lastname: Di Marco
authors.forename: G
authors.initials: G
authors.lastname: Magro
authors.forename: N
authors.initials: N
authors.lastname: Penacho
authors.forename: C C
authors.initials: CC
authors.lastname: Romao
authors.forename: F
authors.initials: F
authors.lastname: Nicoletti
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D001880:Boranes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002248:Carbon Monoxide / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D002254:Carbonates / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003907:Dexamethasone / Q000494:pharmacology / Q000627:therapeutic use; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000175:diagnosis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D051379:Mice; D018991:Myelin Proteolipid Protein / Q000276:immunology*; D009504:Neutrophils / Q000473:pathology; D010446:Peptide Fragments / Q000276:immunology*; D013116:Spinal Cord / Q000187:drug effects / Q000473:pathology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001880:Boranes; D002254:Carbonates; D018991:Myelin Proteolipid Protein; D010446:Peptide Fragments; C435023:myelin proteolipid protein (139-151); C503854:sodium boranocarbonate; D003907:Dexamethasone; D002248:Carbon Monoxide